Avoro Capital Advisors Reduces $41M in Sarepta Therapeutics, Inc. ($SRPT)
Avoro Capital Advisors sold all its shares in SRPT, totaling 2.67 million.
Key Points
- Avoro Capital Advisors completely exited its position in SRPT by selling 2.67 million shares, as per its latest 13F filing.
- SRPT shares traded around $15.17, with major institutional investors like BlackRock and Vanguard increasing their stakes.
- Analysts have mixed views on SRPT, with Citigroup maintaining a 'sell' rating and Oppenheimer reiterating a 'buy' rating.
Avoro Capital Advisors has decided to sell its entire stake in SRPT, according to its latest 13F filing with the SEC. The fund cut its position by 2,674,835 shares, bringing its holdings to zero. This move reflects a 100% reduction in their investment as of the reporting period.
What Changed in Avoro Capital Advisors' SRPT Position
Avoro Capital Advisors had held 2,674,835 shares of SRPT but has now completely exited its position. The fund's decision to sell out indicates a shift in strategy or outlook regarding SRPT, as the shares were entirely liquidated during the reporting period.
Other Institutional Activity in SRPT
In contrast, BlackRock, Inc. increased its holdings in SRPT by 472,024 shares, ending with 14,755,277 shares valued at about $321.1 million. Vanguard Portfolio Management LLC added 6,640,692 shares, bringing its total to the same number, valued at approximately $144.5 million. State Street Corp made a small addition of 13,873 shares, reaching a total of 6,613,314 shares worth around $143.9 million. Meanwhile, AQR Capital Management LLC reduced its stake by 1,363,423 shares, now holding 6,433,112 shares valued at $138.6 million. Two Sigma Investments, LP significantly boosted its position by 2,151,740 shares to a total of 4,593,195 shares, valued at about $99.9 million.
SRPT Stock Snapshot
Shares of SRPT traded around $15.17. The stock's activity is closely watched by investors due to its volatility and the mixed institutional actions surrounding it.
Insider Buying and Selling at Sarepta Therapeutics, Inc.
On June 4, 2026, several insiders, including Michael Andrew Chambers, Deirdre Connelly, Kathryn Jean Boor, Hans Lennart Rudolf Wigzell, Richard Barry, and Claude Nicaise, each purchased 16,875 shares of SRPT. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
Analysts have varied opinions on SRPT. On March 26, 2026, Citigroup maintained its 'sell' rating with a price target of $13. Oppenheimer reiterated its 'buy' rating with a target of $37 on March 19, 2026, and Mizuho maintained a 'buy' rating with a $31 target on March 13, 2026. The consensus among analysts shows a mix of 'buy' and 'sell' ratings, highlighting differing views on SRPT's prospects.
About SRPT
SRPT, a biotechnology company, focuses on developing therapies for rare diseases. The company is involved in research and development to find innovative treatments for conditions with unmet medical needs. Headquartered in the United States, SRPT continues to explore advancements in genetic medicine to improve patient outcomes.
Bottom Line
Avoro Capital Advisors' complete exit from SRPT signals a significant shift in its investment strategy. Investors closely monitor such 13F filings because they provide insights into institutional sentiment, even though they reflect past positions. With diverse institutional actions and mixed analyst ratings, SRPT remains an intriguing stock for market watchers.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.